Senior Scientist, Translational Computational Biology
Bristol-Myers Squibb
- Location
- Cambridge Crossing - MA - US
- Work model
- On-Site
- Level
- Senior
- H-1B history
- 57 approvals (FY2023)
- Posted
- 19h ago
Skills
About this role
Working with Us Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible. Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us . When you join BMS, you are joining a high-achieving team united by a common mission. The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development and across all therapeutic areas at BMS. We do this in close partnership with scientific and clinical experts in the field, both inside and outside the company. We perform innovative science to empower key data-driven decisions across a rich pipeline of next-generation medicines. In doing so, our work transforms the lives of patients, as well as our own lives and careers. Here, you’ll get the chance to grow and thrive through opportunities that are uncommon in scale and scope. You’ll pursue innovative ideas while advancing professionally alongside some of the brightest minds in biopharma.
Position
Summary The Oncology Translational IPS team is seeking a Senior Scientist, Translational Computational Biology, to serve as the computational partner to our oncology drug development programs across discovery, translational research, and early clinical development. You will translate patient-derived molecular, spatial, clinical, and real-world data into biomarker hypotheses, patient stratification strategies, indication prioritization, pharmacodynamic readouts, and decision-grade recommendations. The majority of the role is embedded with oncology drug development programs and clinical development teams. The remainder builds computational capability for the broader portfolio: AI-enabled translational science, spatial biology, and reusable analytical methods. The exact emphasis of that capability work will evolve with portfolio priorities and emerging technologies. This role is for someone who understands drug development, not only data analysis. We are looking for a scientist with a working understanding of the path from target validation and candidate selection through IND-enabling work and early clinical studies (including dose escalation and expansion), and of the strategic role biomarkers play at each stage, who can carry an interpretation into the forum where the decision is actually made. What you will have to work with: Clinical and multi-modal patient-derived datasets from BMS's industry-leading early-stage clinical studies in oncology: the molecular and clinical biomarker data generated by our own early-phase trials, spanning RNA-seq, WES, TCR-seq, ctDNA and CTC, together with flow cytometry, cytokine profiling, IHC, and proteomics. Layered on top of that: spatial transcriptomics and multiplex immunofluorescence across multiple concurrent oncology programs, backed by a pan-cancer spatial atlas license and an H&E-to-mIF platform partnership;